EMERYVILLE, Calif. — August 6, 2025 — Leads & Copy — BioAge Labs, Inc. reported its second quarter 2025 financial results and provided business updates. The company’s oral NLRP3 inhibitor, BGE-102, is on track for Phase 1 initiation in the second half of 2025, with initial data expected by year-end.
BioAge has expanded its APJ agonist pipeline through an option agreement for a novel antibody and the advancement of proprietary oral small molecules. The company has also strengthened its discovery platform through molecular profiling of over 17,000 samples from the European HUNT Biobank.
Kristen Fortney, CEO and co-founder of BioAge, stated that the company achieved key milestones across its clinical pipeline and discovery platform in Q2 2025. She noted the completion of IND-enabling studies for BGE-102, the partnership for APJ agonist antibodies, the filing of patent applications for oral small molecules, and the collaboration with the HUNT Biobank.
In May 2025, BioAge announced the completion of IND-enabling studies for BGE-102, an orally available, brain-penetrant NLRP3 inhibitor initially developed for obesity. Preclinical models demonstrated significant weight loss with BGE-102, both as a monotherapy and in combination with semaglutide. A Phase 1 clinical trial is planned for the second half of 2025.
In June 2025, BioAge entered an exclusive option agreement with JiKang Therapeutics for a novel APJ agonist nanobody. BioAge also filed a U.S. provisional patent application for a new class of orally active APJ agonists.
Also in June 2025, BioAge announced a collaboration with Age Labs AS to profile and analyze samples from the HUNT Biobank in Norway. The company will profile over 17,000 individual samples to generate millions of molecular measurements.
Research and development expenses for the quarter ended June 30, 2025, were $19.8 million, compared to $10.5 million for the same period in 2024. General and administrative expenses were $7.3 million, compared to $4.8 million in 2024. The net loss was $21.6 million, or $0.60 per share, compared to a net loss of $13.6 million, or $7.94 per share, in 2024.
As of June 30, 2025, BioAge had approximately $313.4 million in cash, cash equivalents, and marketable securities, sufficient to fund operations and capital expenses through 2029.
Contacts
PR: Chris Patil, media@bioagelabs.com
IR: Dov Goldstein, ir@bioagelabs.com
Partnering: partnering@bioagelabs.com
